Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Cancer Disparities Progress Report and what oncologists can do to combat them.
|Articles|March 2, 2011
- January 2011
- Volume 5
- Issue 1
Men With Prostate Cancer Should Exercise
Author(s)Marissa Murtaugh
Men with prostate cancer reduce the risk of death from all causes by 46% if they do moderate exercise, such as walking, for 90 minutes a week
Advertisement
Men with prostate cancer reduce the risk of death from all causes by 46% if they do moderate exercise, such as walking, for 90 minutes a week. Men who perform vigorous exercise for >3 hours each week lower their overall mortality risk by 49%, suggests a study published in the Journal of Clinical Oncology. In addition, they reduce their risk of death from prostate cancer by 61% compared with men who exercise <1 hour each week. Outcomes are best for men who exercised routinely before diagnosis and continue to do so.
Articles in this issue
over 15 years ago
Cancer in the Workplaceover 15 years ago
Developing Optimal Patient Medication InformationAdvertisement
Related to this article
Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
Leonard J. Appleman, MD, PhD, discusses prior data with SYNC-T Therapy SV-102 and the ongoing LEGION-100 study in prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
3
Pooled Analysis Reveals Strong Pirtobrutinib Efficacy in Frontline CLL
4
Lutetium Lu 177 Vipivotide Tetraxetan Approval Reshapes the Treatment Landscape for PSMA+ mHSPC
5